文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

供者类型对骨髓纤维化患者异基因造血细胞移植结局的影响:欧洲血液与骨髓移植学会慢性恶性肿瘤工作组的报告

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT.
PubMed 文献 · Am J Hematol · 2025-08-29

该研究分析了2015至2021年间在欧洲血液与骨髓移植学会中心接受首次异基因造血细胞移植的2809例骨髓纤维化患者,比较匹配同胞供者、匹配无关供者、不合无关供者及单倍体供者的结局。中位随访33.5个月后,匹配同胞供者与匹配无关供者结局相当,不合无关供者和单倍体供者因非复发死亡增加而总生存较差。不合无关供者移植物抗宿主病风险高于单倍体供者,但该差异似乎在移植后环磷酰胺应用后消失。

要点

  • 匹配同胞供者与匹配无关供者的骨髓纤维化患者移植结局相当。
  • 不合无关供者和单倍体供者移植总生存较差,与非复发死亡增加相关。
  • 不合无关供者移植物抗宿主病风险高于单倍体供者,但该差异似乎在移植后环磷酰胺应用后消失。

核心结论

  • 在当前实践下,接受匹配同胞供者或匹配无关供者移植的骨髓纤维化患者获得相当的结局;不合无关供者和单倍体供者移植因非复发死亡增加而总生存较差。

研究设计与样本

  • 该研究为欧洲血液与骨髓移植学会中心开展的回顾性分析,纳入2015年至2021年间接受首次异基因造血细胞移植的2809例骨髓纤维化患者。

主要发现

  • 中位随访33.5个月后,匹配同胞供者、匹配无关供者、不合无关供者和单倍体供者的3年总生存率分别为65.8%、61.5%、53.2%和57.7%。
  • 以匹配同胞供者为参照,多变量分析显示供者类型与总生存显著相关(不合无关供者HR为1.63,单倍体供者HR为1.42),与无进展生存相关(不合无关供者HR为1.38),与非复发死亡相关(不合无关供者HR为1.73,单倍体供者HR为1.47)。
  • 供者类型与植入相关(不合无关供者HR为0.72,单倍体供者HR为0.40),与2-4级急性移植物抗宿主病相关(匹配无关供者HR为1.53,不合无关供者HR为1.69,单倍体供者HR为1.49),与广泛型慢性移植物抗宿主病相关(匹配无关供者HR为0.77,单倍体供者HR为0.65)。
  • 供者类型与复发风险无关;在60岁以上患者中,供者类型与结局的相关性与总体研究人群一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selecting the optimal donor is crucial for optimizing results of allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed outcomes based on donor type in 2809 myelofibrosis (MF) patients undergoing first allo-HCT between 2015 and 2021 at EBMT centers. Study outcomes included overall survival (OS), progression-free survival (PFS), relapse, non-relapse mortality (NRM), engraftment, and graft-versus-host disease (GvHD). Four groups were compared: matched sibling donor (MSD, n = 742), matched unrelated donor (MUD, n = 1401), mismatched unrelated donor (MMUD, n = 379) and haploidentical donor (HD, n = 287). After a median follow-up of 33.5 months, 3-year OS rates were 65.8%, 61.5%, 53.2%, and 57.7% for MSD, MUD, MMUD, and HD, respectively. Multivariable analyses (MSD as reference) showed that donor type significantly correlated with OS (HR: 1.63 for MMUD, HR: 1.42 for HD), PFS (HR: 1.38 for MMUD), NRM (HR: 1.73 for MMUD, HR: 1.47 for HD), engraftment (HR: 0.72 for MMUD, HR: 0.40 for HD), grade 2-4 acute GvHD (HR: 1.53 for MUD, HR: 1.69 for MMUD, HR: 1.49 for HD), and extensive chronic GvHD (HR: 0.77 for MUD, HR: 0.65 for HD). Donor type was not associated with relapse risk. In patients over 60 years, correlations between donor type and outcomes were consistent with those in the overall study population. In summary, with current practices, MF patients receiving MSD or MUD grafts achieve comparable outcomes. In contrast, MMUD and HD transplants have worse OS due to increased NRM. MMUD transplants have a higher risk of GvHD than HD transplants, but this difference seems to disappear with post-transplant cyclophosphamide.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hernández-Boluda JC, Sheth V, Iacobelli S, et al. Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2025. PMID: 40879525. doi:10.1002/ajh.70049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。